What is AccuLab Life Sciences?
Headquartered in San Diego, AccuLab Life Sciences operates as a premier preclinical Contract Research Organization (CRO) with a legacy spanning over three decades. The company provides critical development testing and clinical trial support, catering to a diverse clientele ranging from emerging biotech startups to established global pharmaceutical entities. Their core competencies include sophisticated immunogenicity assessments, bioanalysis for clinical trials, and rigorous testing protocols for medical devices and combination products. By prioritizing reproducibility and regulatory compliance, AccuLab serves as a vital link in the drug development value chain, ensuring that complex molecular research is translated into viable, market-ready solutions.
How much funding has AccuLab Life Sciences raised?
AccuLab Life Sciences has raised a total of $2.6M across 1 funding round:
Debt
$2.6M
Debt (2025): $2.6M with participation from Western Alliance Bank
Key Investors in AccuLab Life Sciences
Western Alliance Bank
A prominent financial institution providing specialized banking and financing solutions to the life sciences and technology sectors.
What's next for AccuLab Life Sciences?
With this major enterprise-level funding, AccuLab Life Sciences is positioned to accelerate its infrastructure expansion and enhance its technical capabilities. The strategic allocation of these resources will likely focus on upgrading bioanalytical facilities and deepening the firm's expertise in emerging therapeutic modalities. As the CRO market continues to consolidate, AccuLab's ability to maintain high-fidelity data standards while scaling its service offerings will be a key differentiator. The company is expected to leverage this financial momentum to strengthen its market position, potentially pursuing further technological integration to streamline the path from preclinical discovery to clinical validation for its global partners.
See full AccuLab Life Sciences company page
